tradingkey.logo

Dr Reddy's Laboratories Ltd

RDY
查看詳細走勢圖
14.080USD
+0.120+0.86%
收盤 02/06, 16:00美東報價延遲15分鐘
11.72B總市值
18.02本益比TTM

Dr Reddy's Laboratories Ltd

14.080
+0.120+0.86%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.86%

5天

+4.92%

1月

+2.92%

6月

+3.53%

今年開始到現在

+0.28%

1年

+1.37%

查看詳細走勢圖

TradingKey Dr Reddy's Laboratories Ltd股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Dr Reddy's Laboratories Ltd當前公司基本面數據相對健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在藥品行業排名34/159位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為14.59。中期看,股價處於平穩狀態。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Dr Reddy's Laboratories Ltd評分

相關信息

行業排名
34 / 159
全市場排名
99 / 4521
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Dr Reddy's Laboratories Ltd亮點

亮點風險
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
業績高增長
公司營業收入穩步增長,連續3年增長25.74%
利潤高增長
公司淨利潤處於行業前列,最新年度總收入3.85B美元
高分紅
公司屬於高分紅公司,最新股息支付率11.81%
穩定分紅
公司5年內持續分紅,最新股息支付率11.81%
估值合理
公司最新PE估值18.02,處於3年歷史合理位
機構減倉
最新機構持股115.10M股,環比減少12.26%
景順投資公司持倉
明星投資者景順投資公司持倉,最新持倉306.94K股
活躍度降低
近期活躍度降低,過去20天平均換手率0.23

分析師目標

基於 3 分析師
買入
評級
14.585
目標均價
+4.18%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Dr Reddy's Laboratories Ltd新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Dr Reddy's Laboratories Ltd簡介

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
公司代碼RDY
公司Dr Reddy's Laboratories Ltd
CEOAghanian (Patrick)
網址https://www.drreddys.com/
KeyAI